Aradhana Sarin
President chez ACHILLION PHARMACEUTICALS, INC.
Fortune : 11 M $ au 31/03/2024
Profil
Le Dr Aradhana Sarin est président et directeur d'Achillion Pharmaceuticals, Inc. et directeur financier et vice-président exécutif d'Alexion Pharmaceuticals, Inc. Il est membre du conseil d'administration d'Achillion Pharmaceuticals, Inc. Le Dr Sarin était auparavant employé en tant que directeur indépendant par OraSure Technologies, Inc. et en tant que MD-Healthcare Corporate & Investment Banking par Citizens, Inc. (Austin, Texas) et directeur général de la banque d'investissement dans le secteur de la santé chez UBS AG. Il a obtenu son MBA à la Stanford Graduate School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ASTRAZENECA PLC
0,01% | 31/12/2023 | 82 514 ( 0,01% ) | 11 M $ | 31/03/2024 |
Dernières actualités sur Aradhana Sarin
Postes actifs de Aradhana Sarin
| Sociétés | Poste | Début |
|---|---|---|
| ACHILLION PHARMACEUTICALS, INC. | President | 28/01/2020 |
| ASTRAZENECA PLC | Director of Finance/CFO | 01/08/2021 |
| ANHEUSER-BUSCH INBEV SA/NV | Director/Board Member | 26/04/2023 |
Anciens postes connus de Aradhana Sarin
| Sociétés | Poste | Fin |
|---|---|---|
| CITIZENS, INC. | Corporate Officer/Principal | 01/10/2017 |
| UBS | Corporate Officer/Principal | - |
| ALEXION PHARMACEUTICALS, INC. | Director of Finance/CFO | - |
| ORASURE TECHNOLOGIES, INC. | Director/Board Member | - |
Formation de Aradhana Sarin
| University of Delhi | Doctorate Degree |
| Stanford Graduate School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| CITIZENS, INC. | Finance |
| ASTRAZENECA PLC | Health Technology |
| ORASURE TECHNOLOGIES, INC. | Health Technology |
| ANHEUSER-BUSCH INBEV SA/NV | Consumer Non-Durables |
| Entreprise privées | 3 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
UBS AG
 UBS AG Investment ManagersFinance UBS AG engages in the provision of financial advisory solutions for private and institutional investors, intermediaries, and wealth management clients. The firm focuses on the areas of wealth and asset management, as well as investment banking. It offers retail investment products, global financing services, investment research, bespoke financing, traditional investments, as well as bonds and equities. The company was founded in 1862 and is headquartered in Zurich, Switzerland. | Finance |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
